| Old Articles: <Older 7381-7390 Newer> |
|---|
 |
The Motley Fool
April 27, 2011
Travis Hoium |
Universal Health Services Shares Popped: What You Need to Know Shares of Universal Health Services jumped as much as 14.5% today to reach a new 52-week high after the company announced earnings.   |
The Motley Fool
April 27, 2011
Frank Vinluan |
Inspire's Pink Eye Drug AzaSite Draws Generic Challenge This sought-after drug could soon be facing generic competition. |
The Motley Fool
April 27, 2011
Arundhati Parmar |
Medtronic and Eli Lilly Join Hands to Combat Parkinson's Disease The partnership aims to research and develop a new approach to treating the debilitating disease. |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
April 26, 2011
Luke Timmerman |
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex? |
The Motley Fool
April 25, 2011
Brian Orelli |
Dividend Investors Rejoice! Or Not. Amgen establishes a dividend, investors yawn. |
The Motley Fool
April 25, 2011
Sean Williams |
Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing. |
The Motley Fool
April 25, 2011
Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
The Motley Fool
April 25, 2011
Arundhati Parmar |
St. Jude: New Aortic Replacement Valve Approved St. Jude gets good news. |
| <Older 7381-7390 Newer> Return to current articles. |
